DSM-5 Criteria: Schizophrenia

Box 5.

DSM-5 Diagnosis: Schizophrenia

F Two (or more) of the following, each present for a significant portion of time during
a 1-month period (or less if successfully treated). At least one of these must be
delusions, hallucinations or disorganized speech:
— Delusions
— Hallucinations
— Disorganized speech (e.g., frequent derailment or incoherence)
— Grossly disorganized or catatonic behavior
— Negative symptoms (i.e., diminished emotional expression or avolition)
F Continuous signs of the disturbance persist for at least 6 months. This 6-month period
must include at least 1 month of symptoms (or less if successfully treated) that meet
the above criteria (i.e., active phase symptoms) and may include periods of prodromal
or residual symptoms. During these prodromal or residual periods, the signs of the
disturbance may be manifested only be negative symptoms or by two or more
symptoms listed above present in an attenuated form.
F For a significant portion of time since the onset of the disturbance, level of
functioning in one or more major areas, such as work, interpersonal relations, or self-
care is markedly below the level achieved prior to the onset (or when the onset is in
childhood or adolescence, there is a failure to achieve expected level of interpersonal,
academic, or occupational functioning).
F Schizoaffective disorder and depressive or bipolar disorder with psychotic features
have been ruled out.
F The disturbance is not attributable to the physiological effects of a substance (e.g., a
drug of abuse, a medication) or another medical condition.
F If there is a history of autism spectrum disorder or a communication disorder
of childhood onset, the additional diagnosis of schizophrenia is made only if
prominent delusions or hallucinations, in addition to the other required symptoms of
schizophrenia, are also present for at least 1 month (or less if successfully treated).

floridamedicaidmentalhealth.org
Page 40
 Treatment of Schizophrenia
Note: Treatment recommendations are based on levels of evidence and expert opinion. For a description
of the criteria for each level, see page 4.

Conduct comprehensive assessment and use measurement-based care. Refer to Principles of

Practice on pages 6–11.

Most importantly, assess social support system (housing, family, other caregivers) and
evaluate threats to continuity of care (access to medication, adherence, etc.).

Strongly recommend psychiatric consultation prior to initiation of therapy + psychotherapeutic

medication using a multi-disciplinary approach if treated by a non-psychiatrist.

Level 1 Initial Treatment:

F Monotherapy with an antipsychotic (SGA) other than clozapine*—either oral, or oral
antipsychotic followed by the same SGA-LAI (if tolerable and sufficiently efficacious)
F If initial trial of antipsychotic monotherapy unsuccessful, try monotherapy with another
SGA antipsychotic (either oral or LAI) with low metabolic adverse effects.
*Note: Balance efficacy, side-effects, individual vulnerabilities and preferences. Select a medication with lower
metabolic risk, lower risk of extrapyramidal symptoms (EPS), sedation, and sexual side-effects. For more detail on
LAIs, refer to page 43.
Level 2A If non-adherent or refractory to Level 1:
F Long-acting injectable antipsychotic medication (LAI)
Level 2B If Level 1 is ineffective in at least two antipsychotic trials:
F Clozapine
Level 3 If Levels 1 and 2 are ineffective and/or not well tolerated:
F Diagnostic review and/or consultation
F Clozapine if not tried earlier
F Antipsychotic, including clozapine + electroconvulsive therapy
(ECT)
F Augmentation of clozapine with aripiprazole, lamotrigine,
topiramate or if partial or incomplete response to clozapine
Level 4 If Levels 1, 2, and 3 are ineffective and/or not well
tolerated:
F Two antipsychotics, ideally with different
pharmacological mechanisms* and side-effect profiles
(evidence is weak)
F First generation antipsychotic use
*Full antagonist with partial agonist; loose binding with tight binding

floridamedicaidmentalhealth.org
Page 41
 Table 4. Recommended Medications for the Treatment of
Schizophrenia: Oral Antipsychotics
Chlorpromazine Acute Maintenance
Medication Equivalentsa Therapy Therapyb
First Generation Antipsychotics (FGAs)
Chlorpromazine 100 300–1,000 mg/day 300–800 mg/day
Fluphenazine HCl 2 5–20 mg/day 5–15 mg/day
Haloperidol 2 5–20 mg/day 6–12 mg/day
Loxapine 10 30–100 mg/day 30–60 mg/day
Molindone 10 30–100 mg/day 30–60 mg/day
Perphenazine 8 16–80 mg/day 16–64 mg/day
Thiothixene 5 15–50 mg/day 15–30 mg/day
Trifluoperazine 5 15–50 mg/day 15–30 mg/day
Second Generation Antipsychotics (SGAs)
Aripiprazole N/A 10-30 mg/day 10–30 mg/day
Asenapine N/A 10–20 mg/day 10–20 mg/day
Brexpiprazole N/A 2–4 mg/day 2–4 mg/day
Cariprazine N/A 1.5–6 mg/day 3–6 mg/day
Clozapine N/A 150–800 mg/day 150–800 mg/day
Iloperidone N/A 12–24 mg/day 12–24 mg/day
Lurasidone N/A 40–160 mg/day 40–160 mg/day
Olanzapine N/A 10–30 mg/day 10–20 mg/day
Paliperidone N/A 3–12 mg/day 3–12 mg/day
Quetiapine N/A 300–800 mg/day 300–800 mg/day
Risperidone N/A 2–8 mg/day 2–8 mg/day
Ziprasidone N/A 80–240 mg/day 80–160 mg/day

Notes:
Recommendations may be below FDA maximum approved doses but are based on current evidence and
expert consensus.
Consider lower doses for first episode due to better response and higher side effects to medications in
pharmaceutically naïve patients. Use atypical antipsychotics and avoid haloperidol completely due to
well-documented neuronal cell death caused by haloperidol (and also fluphenazine and perphenazine).
Thioridazine is not recommended due to concerns about ventricular arrhythmias (Torsades de Pointes).
a
Approximate dose equivalent to 100 mg of chlorpromazine (relative potency); it may not be the same at
lower versus higher doses. Chlorpromazine equivalent doses are not relevant to the second generation
antipsychotics and therefore are not provided for these agents.
b
Drug-drug interactions (DDIs) can impact dosing. Maintenance dose should generally be no less than
half of the initial clinically effective dose, as that can result in reduced effectiveness of relapse prevention.

floridamedicaidmentalhealth.org
Page 42
 Treatment of Schizophrenia with Long-Acting Injectable
Antipsychotic Medications (LAIs)

Note: Treatment recommendations are based on levels of evidence and expert opinion. For a description
of the criteria for each level, see page 4.

Conduct a comprehensive assessment and use measurement-based care as found in the

Principles of Practice on pages 6–11.

Assess social determinants (housing, family, other caregivers) and evaluate threats to
continuity of care (access to medication, adherence, etc.).

Strongly recommend psychiatric consultation prior to initiation of therapy + psychotherapeutic

medication using a multi-disciplinary approach if treated by a non-psychiatrist.

Level 1 Initial Treatment:

F After stabilization or obtaining sufficient evidence for efficacy and tolerability, offer
any of the following long-acting injectable antipsychotics (LAI). Base the selection
on past efficacy and tolerability patterns to specific oral or LAI, expected tolerability
advantages*, desired injection intervals, and procedural (oral overlap needed- yes versus
no)/logistic/access/cost considerations:
— Aripiprazole monohydrate
— Aripiprazole lauroxil
— Paliperidone palmitate
— Risperidone microspheres
— Risperidone extended release subcutaneous injectable.
F If initial, adequate trial (minimum 3 to 4 months) of LAI is unsuccessful, try monotherapy
with another LAI from the above group or address potential reasons for efficacy
difficulty on the LAI. Refer to Figure 1: Management of Breakthrough Psychosis with LAI
for options to consider if psychotic symptoms persist despite adequate medication trial.
*Note: Balance efficacy, side-effects, individual vulnerabilities and preferences. Select medication with lower
propensity for metabolic and extrapyramidal side-effects.
Level 2 If Level 1 is ineffective and/or not well tolerated:
F Consider LAI with greater adverse effect risk [olanzapine: post-injection
delirium/sedation syndrome (PDSS); FGA-LAIs: EPS, TD]
— Olanzapine pamoate
— Fluphenazine decanoate
— Haloperidol decanoate
Level 3 If Levels 1 and 2 are ineffective and/or not well tolerated:
F Diagnostic review and/or consultation
F Consider switch to an oral antipsychotic not available as an LAI (if
adherence can be assured)
F Clozapine if not tried earlier
F LAI + electroconvulsive therapy (ECT) or oral antipsychotic
F Clozapine + ECT

Page 43
 Figure 1. Management of Breakthrough Psychosis with
Long-Acting Injectable Antipsychotics (LAIs)

Breakthrough psychotic symptoms

Options to consider
• Rule out / address medical illness or substance use as a contributing factor
• Address stressors and optimize non-pharmacological treatments
• Treat comorbidities
• Ensure proper LAI administration
• Address missed LAI doses appropriately
• Increase LAI dose
• Shorten LAI injection interval (increase LAI AP dose) *

Symptoms
persist
Symptoms
stabilize or Supplement Symptoms
Slowly discontinue oral AP abate LAI with low dose of persist Increase oral AP to
(≥2 weeks after start of corresponding oral AP optimum effective dose†
oral AP coverage) formulation for fast
symptom control†

Evaluate symptoms Evaluate symptoms

initially after 1–2 weeks initially after 1–2 weeks
and then as clinically and then as clinically
appropriate appropriate
Evaluate symptoms
Symptoms Symptoms persist
initially after 1–2 weeks
recur or worsen
and then as clinically
Options to consider appropriate Options to consider
• Rule out or address medical • Rule out or address medical
illness or substance use as a illness or substance use as a
contributing factor Evaluate symptoms contributing factor
• Address stressors and initially after 1–2 weeks • Address stressors and
optimize non-pharmacological and then as clinically optimize non-pharmacological
treatments appropriate treatments
• Treat concomitant medical and • Treat concomitant medical and
psychiatric comorbidities psychiatric comorbidities
• Ensure proper LAI • Ensure proper LAI
administration Improved administration
• Address missed LAI doses • Address missed LAI doses
• Increase LAI dose Not improved • Increase LAI dose
• Shorten LAI injection interval • Shorten LAI injection interval
(LAI dose) * From Correll CU, et al. CNS (LAI AP dose)*
• Re-implement oral AP † Spectrums 2018; 27: 1–17. • Change the oral AP (if given
• Switch LAI adjunctively)
• Switch LAI

*Off-label strategy; based on expert opinion.

†Caution should be exercised with this strategy, because data on the safety of concomitant use of LAI and
oral APs are limited, especially over extended periods of time.
Page 44
 Table 5. Recommended Medications for the Treatment of Schizophrenia:
Long-Acting Injectable Antipsychotics
Dosage
Dose Maintenance Oral Time to
Medication Strengths/ Starting Dose Steady State
Interval Dose Supplementation Peak
Forms
First-Generation Long-Acting Injectable Antipsychotics*
Fluphenazine Varies 25 and 100 mg/mL Varies, 12.5 mg Varies, 12.5 to No 2 to 4 days 2 to 3 months
decanoate ampoules/vials/ 100 mg
syringes
Haloperidol 4 weeks 50 and 100 mg/mL Varies, 50 mg Varies, 300 mg No 6 to 7 days 2 to 3 months
decanoate ampoules
Second-Generation Long-Acting Injectable Antipsychotics*
Aripiprazole Monthly 300, 400 mg vial 400 mg 400 mg 2 weeks 5 to 7 days 400 mg:
monohydrate kits and (300 to 400 mg) 4 to 8 months
(Abilify Maintena®) dual-chamber 300 mg:
syringe 3 to 4 months
(Aripiprazole Monthly for 441; 662; 882; Varies 441 mg to Varies, 441 to 3 weeks if Aristada Initio® 4 days 4 to 6 months
lauroxil (Aristada®) 441 mg dose; 1,064 mg prefilled 1,064 mg** 882 mg is not administered at the
monthly syringes beginning of treatment.
to every 6 If initiating treatment with
weeks for Aristada Initio®, 1 day oral
882 mg dose; supplementation with
bimonthly for aripiprazole 30 mg tablet is
1,064 mg dose required.

Page 45
 Table 5. Recommended Medications for the Treatment of Schizophrenia:

Page 46
Long-Acting Injectable Antipsychotics (continued)
Dosage
Dose Maintenance Oral Time to
Medication Strengths/ Starting Dose Steady State
Interval Dose Supplementation Peak
Forms
Aripiprazole Once at the 675 mg 675 mg Not applicable 1 day (aripiprazole 30 mg 27 days With single IM
lauroxil (Aristada beginning (N/A) tablet) —therapeutic levels injection of
Initio®) to initiate in 4 days Aristada initio®
aripiprazole and 30 mg oral
lauroxil aripiprazole at time
(Aristada®) of first Aristada®
treatment dose, aripiprazole
concentration
reaches therapeutic
levels within 4 days
Olanzapine 2 to 4 weeks 210, 300, 405 mg Varies, up to Varies, up to No 4 days 3 months
pamoate‡ vial kits 300 mg every 300 mg every
(Zyprexa 2 weeks 2 weeks
Relprevv®)
Paliperidone Monthly 39, 78, 117, 156, 234 234 mg (day 1) + 117 mg No 13 days 7 to 11 months
palmitate (Invega mg prefilled 156 mg (day 8) (39 to 234 mg)
Sustenna®) syringes Deltoid only
Paliperidone Once every 3 273, 410, 546, Depends on Varies, 273 to No 30 to 33 Continues steady
palmitate (Invega months 819 mg prefilled once-monthly 819 mg days state at equivalent
Trinza®) syringes paliperidone dose
palmitate (Invega
Sustenna®) dose
 Dosage
Dose Maintenance Oral Time to
Medication Strengths/ Starting Dose Steady State
Interval Dose Supplementation Peak
Forms
Risperidone Once every two 12.5, 25, 37.5, 50 mg Varies, 12.5 mg to Varies, 12.5 mg to 3 weeks 4-6 weeks Steady state
microspheres weeks vial kits 25 mg 50 mg reached after 4
(Risperdal Consta®) injections and
maintained for 4-6
weeks after last
injection
Risperidone Monthly 90 mg, 120 mg 90 mg, 120 mg 90 mg, 120 mg No 4-48 hours 4-6 weeks
extended release powder and liquid
subcutaneous filled syringes
injectable
(Perseris®)

Adapted and updated from: Correll CU, Kane JM, Citrome LL. Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. J Clin
Psychiatry. 2017 Sep/Oct;78(8):1136-1147.
Notes:
For the most updated Florida Medicaid Preferred Drug List, visit https://ahca.myflorida.com/medicaid/Prescribed_Drug/pharm_thera/fmpdl.shtml.
*First-generation long-acting injectable antipsychotic medications (fluphenazine decanoate and haloperidol decanoate) have an oil base. Second-generation
long-acting injectable antipsychotic medications (aripiprazole monohydrate, aripiprazole lauroxil, olanzapine pamoate, 1-month and 3-month paliperidone
palmitate, and risperidone microspheres) have a water base.
** Initial Aristada® dose is based on current oral aripiprazole dose as follows: If oral aripiprazole dose is 10 mg/day, initial Aristada® dose is 441 mg once monthly. If
oral aripiprazole dose is 15 mg/day, initial Aristada® dose is either 882 mg once monthly, 882 mg Aristada every 6 weeks, or 1,064 mg Aristada® every 2 months. If
oral aripiprazole dose is ≥20 mg/day, initial Aristada® dose is 882 mg once monthly.
‡Olanzapine pamoate (Zyprexa Relprevv) requires prescriber certification and patient enrollment with the Risk Evaluation and Mitigation Strategy (REMS) program.
Administration of olanzapine pamoate requires at least 3-hours of post-injection monitoring for post-injection delirium/sedation syndrome (PDSS). Olanzapine has
been found to cause more weight gain and related metabolic side effects than other SGAs.

Page 47
 Summary: Treatment of Schizophrenia with LAIs

Christoph U. Correll, M.D.

Professor of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of
Medicine at Hofstra / Northwell
Investigator, Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research
Medical Director, Recognition and Prevention (RAP) Program, The Zucker Hillside Hospital
Department of Psychiatry

Main Questions:
n 1. Are LAIs more effective than placebo?
Yes.

All approved LAIs have demonstrated efficacy for people with schizophrenia. In the USA
(Correll et al., 2017), these agents include:

F First-generation antipsychotics:
— Fluphenazine decanoate
— Haloperidol decanoate
F Second-generation antipsychotics:
— Aripiprazole monohydrate
— Aripiprazole lauroxil
— Olanzapine pamoate
— Paliperidone palmitate
— Risperidone microspheres
— Risperidone extended release subcutaneous injectable
n 2. Are LAIs more effective than oral antipsychotics?
Yes, in many studies and settings, with some non-differential results, but very rare/virtually
no data indicating better efficacy for oral antipsychotics.

Efficacy of LAIs versus oral antipsychotics depends on the study design and included
population (Correll et al., 2016). In randomized clinical trials (RCTs) that include patients
with better illness insight, less severity/complexity of the disease and better/monitored
adherence, LAIs were not more efficacious than placebo (Kishimoto et al., 2014). In mirror
image studies (Kishimoto et al., 2013) and cohort/database studies (Kishimoto et al., 2018)
that enroll more generalizable patients, LAIs were superior to oral antipsychotics regarding
relapse, hospitalization, and all-cause discontinuation risk, despite greater illness severity in
patients started on LAIs versus oral antipsychotics in real-world studies. Additionally, LAIs
have been associated with a 20–30% reduced all-cause mortality versus oral antipsychotics
(Taipale et al., 2018).

floridamedicaidmentalhealth.org
Page 48
 Summary: Treatment of Schizophrenia with LAIs
(continued)

n 3. Are LAIs tolerable?

Yes.

Generally, the adverse effects of LAIs are predictable from knowledge of the adverse effect
potential of the oral counterpart and can be tested in an individual patient during lead in
treatment with the oral antipsychotic.

Comparing 119 adverse events in patients randomized to an LAI or the same medication
given in an oral formulation, 115 (97%) were not different, including discontinuation
due to adverse event or mortality. Regarding 3 adverse effects [akinesia, (stiffness)
with first generation antipsychotics (FGAs), increase in low density lipoprotein
cholesterol, and anxiety], oral antipsychotics had lower events, while prolactin levels and
hyperprolactinemia were lower in LAI treated patients (Misawa et al., 2016). Injection pain
and injection site reactions are generally mild and infrequent (Correll et al., 2016).

Based on data with FGA-LAIs, there is no current indication that the outcome of
neuroleptic malignant syndrome is worse when it occurs during LAI versus oral
antipsychotic treatment, as management is symptomatic (Glazer and Kane, 1992).

An exception from the rules above is olanzapine pamoate, which is highly blood soluble
and which can, in 1/1,100–1,200 injections, lead to a post-injection somnolence, sedation,
and coma syndrome (known as post injection delirium/sedation syndrome, or PDSS).
Therefore, at least 3 hours of post-injection observation for the duration of treatment with
olanzapine pamoate is required.

n 4. Are there special populations in whom LAIs should especially be considered or

not considered?
While prior guidelines relegated LAI use to a third-tier treatment step, unless patients were
non-adherent, had multiple relapses or preferred LAIs, recent evidence and guidance
includes offering LAIs to potentially all patients as a treatment option and also considering
them for prevention of future non-adherence and relapse/deterioration (Llorca et al., 2013;
Malla et al., 2013; Correll et al., 2016; Brugnoli et al., 2016; Galletly et al., 2016; Howes et al.,
2017; Sajatovic et al., 2018).

F Populations and clinical scenarios in which first-line use of LAIs should be

considered include:
— Past or current nonadherence leading to deterioration
— Low illness insight
— Poor cognition
— Dangerousness
— Homelessness
— Poor support system
— Suicidality
floridamedicaidmentalhealth.org
Page 49
 Summary: Treatment of Schizophrenia with LAIs
(continued)

F Emerging areas of first-line use of LAIs include:

— High level of insight
— High functioning (to prevent loss of function)
— Anticipated nonadherence over time
— Stabilized first episode and early phase patients (high future non-adherence
risk, most to lose from future potential relapse)
— Treatment-refractory patients who may be “pseudo-resistant” due to covert
levels of non-adherence
The only contraindication for deep intramuscular injectable LAIs is significant
anticoagulation, presenting a risk for internal bleeding/large hematomas. Needle phobia
should be addressed with cognitive behavioral therapy (CBT).

n 5. How should break-through symptoms during LAI treatment be addressed?

Review and address non-pharmacologic reasons for exacerbation, such as substance use,
other comorbid psychiatric or medical illness, psychosocial stressors, etc. Rule out drug-
drug interactions and inappropriate injection (insufficient mixing prior to injection, lack of
deep intramuscular injection, accumulation of late injection visits, etc.) (Correll et al., 2018).

If the above does not resolve the issue or immediate action is needed, add the same
antipsychotic in oral formulation in an attempt to increase the dose. Generally, try to avoid
polypharmacy with different antipsychotics, as the evidence for efficacy and safety is
lacking (Galling et al., 2017; Correll et al., 2017).

If efficacy is reestablished and the higher dose is tolerated, at the next injection interval,
use a higher LAI dose that corresponds to that combined LAI + oral dose. If already at the
highest dose, consider changing injection site (deltoid injections lead to higher peak levels
but shorter half-life, gluteal injection leads to lower peak levels but longer half-life), change
to shortest FDA-approved injection interval (if not already done), or consider off-label
strategy of shortening the injection interval (Correll et al., 2016; Correll et al., 2018).

n 6. How should LAIs best be offered in clinical care?

LAIs need to be destigmatized and presented not as a last resort or in a punitive or
mistrustful way, but rather as a highly effective treatment option that offers for many
patients a greater likelihood of stability and improved ability to focus on recovery. Data
suggest that motivational interviewing and shared decision making, which do not pass
the decision simply back to the patient, but that present the evidence and advantages in a
respectful and authoritative (yet not authoritarian) way, may yield best results (Correll et al.,
2016; Weiden et al., 2017). Inclusion of caregivers/significant others and/or peer counselors
should also be considered (Correll et al., 2016). Furthermore, buy-in by and training of all
team members can yield very high acceptance of LAIs, with such training, including role
play, having been show to result in at least one LAI injection within 3 months of service
engagement in >75% of first-episode and early-phase patients with schizophrenia (Kane et
al., 2019).
floridamedicaidmentalhealth.org
Page 50
 Summary: Treatment of Schizophrenia with LAIs
(continued)

References:
Brugnoli R, Rapinesi C, Kotzalidis GD, Marcellusi A, Mennini FS, De Filippis
S, Carrus D, Ballerini A, Francomano A, Ducci G, Del Casale A, Girardi P. Model of Management (Mo.
Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and
recovery with long-acting injectable antipsychotics (LAIs). Riv Psichiatr. 2016 Mar-Apr;51(2):47-59.
Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, Kane JM. The Use of Long-
Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. J Clin Psychiatry.
2016;77(suppl 3):1-24.
Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42
Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in
Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic
Evidence. JAMA Psychiatry. 2017 Jul 1;74(7):675-684.
Correll CU, Sliwa JK, Najarian DM, Saklad SR. Practical considerations for managing breakthrough
psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable
antipsychotics. CNS Spectr. 2018 Dec 27:1-17.
Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, McGorry P, Nielssen
O, Tran N. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines
for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016
May;50(5):410-72.
Galling B, Roldán A, Hagi K, Rietschel L, Walyzada F, Zheng W, Cao XL, Xiang YT, Zink M, Kane JM,
Nielsen J, Leucht S, Correll CU. Antipsychotic augmentation vs. monotherapy in schizophrenia:
systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017
Feb;16(1):77-89.
Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin
Psychiatry. 1992 Dec;53(12):426-33. Kishimoto T, Hagi K, Nitta M, Leucht S, Olfson M, Kane JM,
Correll CU. Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients with
Schizophrenia: A Metaanalysis of Prospective and Retrospective Cohort Studies. Schizophr Bull.
2018 Apr 6;44(3):603-619.
Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield
MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson
M, Drake RJ, Dursun S, Ebdrup BH, Elkis H, Falkai P, Fleischacker WW, Gadelha A, Gaughran
F, Glenthøj BY, Graff-Guerrero A, Hallak JE, Honer WG, Kennedy J, Kinon BJ, Lawrie SM, Lee J,
Leweke FM, MacCabe JH, McNabb CB, Meltzer H, Möller HJ, Nakajima S, Pantelis C, Reis Marques
T, Remington G, Rossell SL, Russell BR, Siu CO, Suzuki T, Sommer IE, Taylor D, Thomas N, Üçok
A, Umbricht D, Walters JT, Kane J, Correll CU. Treatment-Resistant Schizophrenia: Treatment
Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on
Diagnosis and Terminology. Am J Psychiatry. 2017 Mar 1;174(3):216-229.
Kane JM, Schooler NR, Marcy P, Achtyes ED, Correll CU, Robinson DG. Patients With Early- Phase
Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting
Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial. J Clin
Psychiatry. 2019 Apr 23;80(3). pii: 18m12546.
Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable vs. oral
antipsychotics in schizophrenia: A systematic review and meta-analysis of mirror-image
studies. J Clin Psychiatry. 2013 Oct;74(10):957-65.
floridamedicaidmentalhealth.org
Page 51
 Summary: Treatment of Schizophrenia with LAIs
(continued)

Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane

JM, Correll CU. Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in
Schizophrenia: A Meta-Analysis of Randomized Trials. Schizophr Bull. 2014 Jan;40(1):192-213.
Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. Guidelines for the use
and management of long-acting injectable antipsychotics in serious mental illness. BMC
Psychiatry. 2013 Dec 20;13:340.
Malla A, Tibbo P, Chue P, Levy E, Manchanda R, Teehan M, Williams R, Iyer S, Roy MA. Long-acting
injectable antipsychotics: recommendations for clinicians. Can J Psychiatry. 2013 May;58(5 Suppl
1):30S-5S.
Misawa F, Kishimoto T, Hagi K, Kane JM, Correll CU. Safety and tolerability of long-acting
injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies
comparing the same antipsychotics. Schizophr Res. 2016 Oct;176(2-3):220-30.
Sajatovic M, Ross R, Legacy SN, Correll CU, Kane JM, DiBiasi F, Fitzgerald H, Byerly M. Identifying
patients and clinical scenarios for use of long-acting injectable antipsychotics - expert
consensus survey part 1. Neuropsychiatr Dis Treat. 2018 Jun 8;14:1463-1474.
Taipale H, Mittendorfer-Rutz E, Alexanderson K, Majak M, Mehtälä J, Hoti F, Jedenius E, Enkusson D,
Leval A, Sermon J, Tanskanen A, Tiihonen J. Antipsychotics and mortality in a nationwide cohort
of 29,823 patients with schizophrenia. Schizophr Res. 2018 Jul;197:274-280.
Weiden PJ, Roma RS, Velligan DI, Alphs L, DiChiara M, Davidson B. The challenge of offering
long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist
recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry.
2015 Jun;76(6):684-90.

floridamedicaidmentalhealth.org
Page 52